Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0360-3016(98)00503-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Microstrip plastic scintillating detector system for quality assurance in synchrotron microbeam radiotherapy.
Sci Rep
January 2025
Universite Claude Bernard Lyon 1, INL, UMR5270, CNRS, INSA Lyon, Ecole Centrale de Lyon, CPE Lyon, 69622, Villeurbanne, France.
Synchrotron microbeam radiotherapy (MRT), which has entered the clinical transfer phase, requires the development of appropriate quality assurance (QA) tools due to very high dose rates and spatial hyperfractionation. A microstrip plastic scintillating detector system with associated modules was proposed in the context of real-time MRT QA. A prototype of such a system with 105 scintillating microstrips was developed and tested under MRT conditions.
View Article and Find Full Text PDFHyper-fractionated radiotherapy as a bridging strategy to enhance CAR-T efficacy by regulating T-cell co-stimulatory molecules in relapsed/refractory diffuse large B-cell lymphoma.
Front Immunol
December 2024
Department of Hematology, Peking Union Medical College Hospital, Beijing, China.
Background: Bridging therapy can prevent patients from disease progression while waiting for CAR-T cell preparation. Hyper-fractionated radiotherapy can achieve an effective target dose within a short period, minimize radiation damage, and may modify immune environment compared to conventional radiotherapy.
Aims: This study aims to investigate the efficacy and safety of bridging hyper-fractionated radiotherapy in combination with CAR-T therapy for relapsed/refractory diffuse large B-cell lymphoma.
Surgical management of skull base and spinal chordomas: A case series with comprehensive review of the literature.
N Am Spine Soc J
December 2024
Department of Neurosurgery, University of Iowa Carver, College of Medicine, Iowa City, IA, United States.
Background: Chordomas are rare, slow growing, locally aggressive malignant bone tumors that arise from remnants of the embryonic notochord with variable presenting symptoms depending on tumor location.
Methods: All patients with craniospinal chordoma managed at our institution between 1982 and 2023 were retrospectively reviewed. Demographics, tumor characteristics, clinical course and treatment, and long-term neurological and survival outcomes were collected.
Risk factors for treatment-related sensorineural hearing loss and hearing aid use in medulloblastoma patients: an observational cohort study.
Strahlenther Onkol
October 2024
Department of Radiation Oncology, Münster University Hospital, Albert-Schweitzer-Campus 1, Building A1, 48149, Münster, Germany.
Purpose: This study aimed to analyze treatment-related risk factors for sensorineural hearing loss (SNHL) and an indication for hearing aids (IHA) in medulloblastoma patients after craniospinal radiotherapy (CSRT) and platin-based chemotherapy (PCth).
Methods: A total of 58 patients (116 ears) with medulloblastoma and clinically non-relevant pre-treatment hearing thresholds were included. Cranial radiotherapy and PCth were applied sequentially according to the HIT 2000 study protocol or post-study recommendations, the NOA-07 protocol, or the PNET (primitive neuroectodermal tumor) 5 MB therapy protocol.
Long-term outcome of the Milano-HART strategy for high-risk medulloblastoma, including the impact of molecular subtype.
Neuro Oncol
September 2024
Integrated Biology Platform, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy.
Article Synopsis
- - The study focused on treating high-risk M+ medulloblastoma patients through a specific chemotherapy and radiation protocol, including multiple high-dose drugs and tailored dosages based on age and response to treatment.
- - Out of 89 enrolled patients, the median age was 8.8 years, and the study reported 5-year overall survival at 75.9% and 15-year event-free survival at 66.5%, with some negative outcomes linked to disease progression during treatment.
- - Subgroup analysis indicated that patients with Sonic Hedgehog (SHH) tumors and those with certain genetic mutations had significantly worse event-free survival rates compared to other subgroups in the study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!